QC
BMRN icon

Quadrature Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Quadrature Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$817K Buy
14,276
+4,784
+50% +$262K 0.01% 802
2026
Q1 		$536K Sell
9,492
-2,653
-22% -$155K 0.01% 772
2025
Q4 		$722K Buy
12,145
+4,449
+58% +$242K 0.01% 601
2025
Q3 		$417K Sell
7,696
-24,696
-76% -$1.41M ﹤0.01% 581
2025
Q2 		$1.78M Buy
+32,392
New +$1.91M 0.03% 312

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Quadrature Capital's BMRN Position: Q2 2026 in Review

Quadrature Capital increased its BioMarin Pharmaceuticals (BMRN) stake by 50% in Q2 2026, buying an estimated $262K and bringing the position to 14,276 shares worth $817K. The position accounts for 0.01% of the portfolio, ranked #802.

Quadrature Capital first reported a position in BMRN in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.78M in Q2 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Quadrature Capital held 14,276 shares of BioMarin Pharmaceuticals worth $817K as of Q2 2026.
  • Quadrature Capital bought 4,784 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $262K.
  • BioMarin Pharmaceuticals made up 0.01% of Quadrature Capital's portfolio in Q2 2026, its #802 holding.
  • Quadrature Capital first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Quadrature Capital's BioMarin Pharmaceuticals position peaked at $1.78M in Q2 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.